위암환자의 복강내에 투여한 Mitomycin C-Carbon Particle의 Mitomycin 용출에 관한 연구

노승무,조영훈,정경수,오정연,김진향,양준묵,강대영,송규상,조준식,최선웅,이진호,민병무,김용백,김창식,박근성,인현빈,정현용,김학용 충남대학교 의과대학 지역사회의학연구소 1998 충남의대잡지 Vol.25 No.1

Locoregional recurrence is the most common type of recurrence in surgical operation of gastric adenocarcinoma, and peritoneal dissemination is one of the most difficult problems in advanced gastric adenocarcinoma treatment. Because the peritoneal cavity is the most common site of the first recurrence after gastric cancer resection, intraperitoneal chemotherpy seems a logical choice for cancer chemotherapy. The Mitomycin C(MMC) adsorbed by the activated charcoal particles(CH) is relatively released when the drug concentration surrounding the carbon particles becomes low in the peritoneum of the peritoneal cavity. For the intraperitoneal chemotherapy on the advanced gastric adenocarcnoma, mitomycin C adsorbed on activated carbon particles was administered in the peritoneal cavity just before abdominal wall closure. The closed drainage tubes were inserted in the peritoneal cavity and clamped for tuo hours after completion of operation. MMC concentrations were serially measured in peritoneal fluid, plasma and urine at 2hour, 48 hour, 72 hour and 168 hour following its administration in order to study the efficacy of the MMC-CH as a drug delivery system. There were minimal toxicities in born marrow, liver, and gastrointestinal system after intraperitoneal MMC-CH administration. The data of this study suggested that MMC-CH may have a somewhat more beneficial effect than surgery alone when administered in optimal dose and schedules, but the MMC concentration of the peritoneal fluid was not sufficient to eradicate remnant cancer cells, and effective duration of maintenance was only below 24 hours in the peritoneal fluid and plasma.

T 세포활성항원 CTLA-4의 기능에 관한 연구 : T 세포에서 표적세포 살해능과 CTLA-4 발현과의 연관성 Target Cytotoxicity of T Cell Correlates with CTLA-4 Production

노만택,조양자,김용식,최용,조보현,최장원,정용훈 大韓免疫學會 1996 大韓免疫學會誌 Vol.18 No.4

CTLA-4, a T cell activation antigen and a homologue of CD28, was originally identified as a gene by a series of reverse genetic approaches. While CD28 molecule has been characterized well as a stimulator of T-cell function via enhanced lymphokines production and stablilization of those mRNA, most of the functions of CTLA-4 remain unknown. It has been widely accepted that CTLA-4 functions as an immune suppressor which is down-regualting the function of CD28. We previously showed that 34 KD form of this antigen mainly expressed CD8+ subset, a cytotoxic or suppressor, of activated peripheral blood lymphocyte. Based on our previous finding this study was conducted to further characterize immunological function of CTLA-4 especially in terms of involvement of this molecule in T-cell effector function mediating target cell cytotoxicity. 4 human T cell clones with different target cytotoxicities were employed in this study. NBL46 (CD4+) and NBL77 (CD8+) were cytotoxic and NBL32 (CD4+) and NBL58 (CD 8+) were non-cytotoxic to target LBF cell in target cell chromium release assay. And in Western blot assay 34 kD antigen was detected in NBL46 (CD4+) and NBL77 (CD8+) clones but not in NBL32 (CD4+) and NBL58 (CD8+) clones. It was summarized that expression of the CTLA-4 antigen was associated with cytotoxicity but not with subset phenotypes of T cells. In conclusion CD8+ T subset of PHA-stimulated PBL was major and only CTLA-4 producer and this molecule was induced during mid to late stage of T cell activation. The cytotoxicity of T cell clones to its target cell was directly correlated with its CTLA-4 production and vice versa. And it was highly suggested that primary function of CTLA-4 may involved in T cell effector function which mediates target cell killing.

투기종목 선수들의 무산소성 역치의 특성

조현철,송순천,김춘경,김의영,안용규,이규석,김학렬 龍仁大學校 體育科學硏究所 1991 體育科學硏究論叢 Vol.1 No.1

The purpose of the present study is to determine the levels of maximal oxygen uptake and anaerobic threshold of boxing players(n=23), ken-do players(n=18), Judo players(n=12), T.D.K players(n=18). Treadmill test was used to measure maximal state and anaerobic threshold of metabolic variables. Treadmill exercises protocol was 2-min incremental test from an initial work load of 0MPH(grade : 0%) to all-out by step of 1.0MPH(grade : 2%). The results of measurement was as follows : 1. Absolute(1/min) and relative(ml/kg/min) maximal oxygen uptake was highest(5.08l/min, 65.01 ml/kg/min) in Judo layers, followed in order by the T.D.K players (4.37l/min, 64.74 ml/kg/min), Boxing players(4.18) l/min, 63.19 ml/kg/min) and ken-do players(3.81l/min, 58.65 ml/kg/min). It is not significant difference in the relative maximal oxygen uptake, but is significant difference between group in the absolute maximal oxygen uptake(p<0.001) 2. AT-VO₂(l/min) and AT-VO₂(ml/kg/min) in the anaerobic threshold was highest (3.71 l/min, 47.28 ml/kg/min) in Judo players, followed in order by the T.K.D players(3.29 l/min, 48.75 ml/kg/min), boxing players(2.90 l/min, 43.91 ml/kg/min) and ken-do players(2.82 l/min, 43.52 ml/kg/min). It is not significant difference in the AT-V02(ml/kg/min), but is significant difference between group in the AT-V02(l/min). (p<0.001) 3. %HRmax and %V 02max in the anaerobic threshold was not significant difference between group.

리마틸 정(부시라민 100㎎)에 대한 부시린 정의 생물학적 동등성

조혜영,이문석,오인준,김동현,문재동,이용복 한국약제학회 2001 Journal of Pharmaceutical Investigation Vol.31 No.2

Bucillamine is a novel cysteine derivative with two free intramolecular sulfhydryl groups, and has a preventive and therapeutic effect on adjuvant arthritis, suggesting its antirheumatic action. With respect to the effect on the immune system, bucillamine-exerted such immunoregulating actions are to nomalize an excessive reduction or acceleration in immune reaction. It is useful not only in patients with early stage of rheumatoid arthritis (RA) but also in those with active RA retained for more than 10 years. The purpose of the present study was to evaluate the bioequivalence of two bucillamine tablets, Rimatil^TM (Chong Kun Dang Pharmaceutical Co., Ltd.) and Bucilin^TM (Kuhn Il Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 23.67±2.09 years in age and 65.03±6.73 kg in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After three tablets containing 100 mg of bucillamine per tablet were orally administered, blood was taken at predetermined time intervals and the concentrations of bucillamine in serum were determined using GC/MS with mass selective detector. Pharmacokinetic parameters such as AUC_t, C_max, and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t, C_max and T_max between two tablets were -0.29%, -3.20% and 8.22%, respectively, when calculated against the Rimatil^TM tablet. The powers (1-β) for AUC_t and C_max were 84.31 % and 91.16%, respectively. Minimum detectable differences (Δ) at α=0.10 and 1-β=0.8 were less than 20% (e.g., 18.58% and 16.51% for AUC_t and C_max respectively). The 90% confidence intervals were within ±20% (e.g., -12.77∼12.20 for AUC_t and -14.30∼7.90 for C_max). Two parameters met the criteria of KFDA for bioequivalence, indicating that Bucilin^TM tablet is bioequivalent to Rimatil^TM tablet.

디푸루칸 캅셀(플루코나졸 50 mg)에 대한 플루코나 캅셀의 생물학적 동등성

조혜영,강현아,이석,오인준,임동구,문재동,이용복 한국약제학회 2003 Journal of Pharmaceutical Investigation Vol.33 No.2

Fluconazole is an orally active bis-triazole antifungal agent, which is used in the treatment of superficial and systemic candidiasis and in the treatment of cryptococcal infections in patients with the acquired immuno deficiency syndrome (AIDS). The purpose of the present study was to evaluate the bioequivalence of two fluconazole capsules, Diflucan(Pfizer Pharmaceuticals Korea Inc.) and Flucona (Korean Drug Pharmaceuticals Co., Ltd.), according to the guidelines of Korea Food and Drug Administration(KFDA). The fluconazole release from the two fluconazole capsules in vitro was tested using KP Ⅶ Apparatus Ⅱ method at 0.1M hydrochloride dissolution media. Twenty normal male volunteers, 23.60±1.88 years in age and 63.57±6.17㎏ in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After three capsules containing 50㎎ as fluconazole was orally administered, blood was taken at predetermined time intervals and the concentrations of fluconazole in serum were determined using HPLC method with UV detector. The dissolution profiles of two fluconazole capsules were very similar at 0.1M hydrochloride dissolution media. Besides, the pharmacokinetic parameters such as AUC_t, C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed AUC_t and C_max and untransformed T_max. The results showed that the differences in AUC_t, C_max and T_max between two capsules based on the Diflucan were 4.96%, 5.65% and -13.76%, respectively. There were no sequence effects between two capsules in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., log(1.01)∼log(1.08) and log(1.00)∼log(1.12) for AUC_t and C_max respectively), indicating that Flucona capsule is bioequivalent to Diflucan capsule.

배양 표피세포 이식의 생착에 관한 연구

조용근,홍성표,장충현,이두형 大韓成形外科學會 1991 Archives of Plastic Surgery Vol.18 No.1

We cultured the keratinocytes from different donors for 3 weeks and the cultured keratinocyte sheets were applied to the 15 cases of patients who had hypertrophic scars on their extremities. (auto-??allografting) And the applied keratinocyte sheets were studied for the adaptation, growth ?? differentiation with light and electron-microscopy. The results were as follows; 1. Grafted epidermal cells started differentiation from second week post-grafting and showed a similar appearance to the normal epidermis at fourth week post-grafing. 2. Keratohyalind granules were seen from fourth week post-grafting and showed a normal appearance at fifth month post-grafting. 3. Immature desmosome-tonofilament complexes were seen at cultured epidermal sheet and showed a normal appearance at fifth month post-grafting. 4. Rete ridges showed its appearance at fourth week post-grafting and showed a normal appearance at fifth month post-grafting. 5. Fine structures of epidermo-graft bed junction showed a discontinuous appearance at second week post-grafting and showed a normal continuous appearance at fifth month post-grafting. In summary, the 'take' of grafted epidermal sheets begins at fourth week post-grafting and completed at fifth month post-grafting.

새로운 경신규칙의 신경망을 이용한 디지털회로의 효율적인 시험패턴 생성

조용현 대구효성가톨릭대학교 응용과학연구소 1999 응용과학연구논문집 Vol.7 No.-

This paper presents an efficient test pattern generation for digital circuits by using neural networks which make use of a new update rule. a new update rule is based on the golbal optimization using both the steepest descent and the dynamic tunneling. The steepest descent is applied for high-speed update and the dynamic tunneling is also applied for global update. The neural network of the proposed update rule has been applied for test pattern generations to the parity generator to evaluate the performance. The simulation results show that the performance of proposed update rule is superior to that of the Hopfield model using the conventional update rule.

뉴로-퍼지 모델의 최적화 기법 개발

조현찬,서재용 한국기술교육대학교 1999 論文集 Vol.6 No.1

This paper presents an approach to obtain a reduced neuro-fuzzy model for a plan. To decide which rules we may eliminate dependancy in rough set theory is used. The rapid convergence of the number of the redundant rules must be accomplished by our method. We don't need to cluster the input space from the raw data and furthermore don't worry about ε-completeness, which we have to consider when clustering the initial input space. However many rules it has, neuro-fuzzy model can be reduced rapidly for dependency seek for every rule worthless. Experimental results demonstrate the effectiveness of using dependency to measure the contribution of any rule to the model.

공액 기울기법과 동적터널링 시스템의 조합에 의한 다층신경망의 성능개선

조용현 대구효성가톨릭대학교 1997 연구논문집 Vol.55 No.2

This paper proposes and efficient learning method for improving the training performance of the neural networks using a hybrid of conjugate gradient algorithm and dynamic tunneling system. The conjugate gradient algorithm, which is the fast gradient algorithm, is applied for high speed optimization. The dynamic tunneling system, which is the deterministic method with tunneling phenomenon, is applied for global optimization. Converging to the local minima is estimated by dynamic tunneling system. The proposed method has been applied to the parity check and pattern classification. The simulation results show that the performance of proposed method is superior to those of a gradient descent algorithm and a hybrid of gradient descent and dynamic tunneling system.

그란닥신 정(토피소팜 50mg)에 대한 토핌 정의 생물학적 동등성

조혜영,정현철,허수희,임동구,문재동,이용복 한국약제학회 2001 Journal of Pharmaceutical Investigation Vol.31 No.2

Tofisopam is a new type of tranquilizer valuable for the relief of anxiety and tension in a wide range of emotional disorders. Tofisopam has the therapeutic characteristics of a minor tranquilzer and a mild stimulatory effect. The purpose of the present study was to evaluate the bioequivalence of two tofisopam tablets, Grandaxin^TM (Hwan In Pharmaceutical Co., Ltd.) and Tofim^TM (Kyung Dong Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 23.11±2.83 years in age and 65.43±7.64 kg in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After one tablet containing 50 mg of tofisopam was orally administered, blood was taken at predetermined time intervals and the concentrations of tofisopam in serum were determined using HPLC method with UV detector. The pharmacokinetic parameters such as AUC_t C_max and T_max were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC_t C_max and T_max between two tablets based on the Grandaxin^TM were -5.59%, 2.22% and -13.18%, respectively. Minimum detectable differences (Δ) at α=0.10 and 1-β=0.8 were less than 20% (e.g., 14.95% and 19.34% for AUC_t and C_max respectively). The powers (1-β) at α=0.10, Δ=0.2 for AUC_t and C_max were 95.21% and 81.93%, respectively. The 90% confidence intervals were within ±20% (e.g., -15.64∼4.45 and -10.77∼15.21 for AUC_t and C_max respectively). Two parameters met the criteria of KFDA for bioequivalence, indicating that Tofim^TM tablet is bioequivalent to Grandaxin^TM tablet.